As the precursor of NAFLD, deleting AKT2, the downstream target of PTEN signal, can block the development of NASH and reduce the development of liver fibrosis, which also reduces the occurrence of NAFLD from another development process (23). The gene discussed is AKT2; the disease is metabolic dysfunction-associated steatohepatitis.